| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8662232 | International Journal of Cardiology | 2018 | 9 Pages |
Abstract
Aspirin remained neutral with respect to overall survival, cardiovascular mortality and arterial ischemic events. It reduced venous thromboembolic events at the expense of perioperative major bleedings. Thus, this analysis supports recommendations against perioperative aspirin continuation/initiation in cardiovascular disease patients at intermediate risk, as well as recommendations of aspirin for VTE prophylaxis in orthopedic patients only.
Keywords
AHAPCIVTERCTTIAPRISMAHTNACCPASAPAODACCHLPN/ARandomized controlled trialAspirinMyocardial infarctionPreferred Reporting Items for Systematic Reviews and Meta-AnalysesAcetyl salicylic acidEuropean Society of CardiologyAmerican Heart AssociationBARCNSARPeripheral artery occlusive diseasecardiovascular diseaseThromboembolismVenous thromboembolismCABGtransient ischemic attackESCBleedingBleeding Academic Research ConsortiumNot availableDiabetes mellitusCVDLevel of evidenceStrokeSurgeryconfidence intervalHypertensionLoEpercutaneous coronary interventionMortalityodds ratioHyperlipoproteinemiaCoronary artery bypass graftAmerican College of CardiologyAmerican College of Chest Physicians
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Georg Wolff, Eliano Pio Navarese, Maximilian Brockmeyer, Yingfeng Lin, Athanasios Karathanos, Michalina KoÅodziejczak, Jacek Kubica, Amin Polzin, Tobias Zeus, Ralf Westenfeld, Felicita Andreotti, Malte Kelm, Volker Schulze,